Silvant Capital Management’s Biogen BIIB Stock Holding History

Silvant Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-164	Closed	-$39K	–	335
2021 Q4	$39K	Hold	164	–	–	0.01%	287
2021 Q3	$46K	Hold	164	–	–	0.01%	276
2021 Q2	$57K	Hold	164	–	–	0.01%	268
2021 Q1	$46K	Hold	164	–	–	0.01%	280
2020 Q4	$40K	Hold	164	–	–	0.01%	276
2020 Q3	$47K	Hold	164	–	–	0.01%	260
2020 Q2	$44K	Hold	164	–	–	0.01%	266
2020 Q1	$52K	Hold	164	–	–	0.01%	234
2019 Q4	$49K	Hold	164	–	–	0.01%	270
2019 Q3	$38K	Sell	164 -36	-18%	-$8.38K	0.01%	285
2019 Q2	$47K	Hold	200	–	–	0.01%	288
2019 Q1	$47K	Sell	200 -17,068	-99%	-$5.37M	0.01%	278
2018 Q4	$5.2M	Sell	17,268 -486	-3%	-$155K	1.04%	22
2018 Q3	$6.27M	Sell	17,754 -2,891	-14%	-$995K	0.77%	38
2018 Q2	$5.99M	Sell	20,645 -233	-1%	-$65.5K	0.74%	42
2018 Q1	$5.72M	Buy	+20,878	New	+$6.48M	0.73%	50

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Silvant Capital Management's BIIB Position: Q1 2022 in Review

Silvant Capital Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 164 shares — an estimated $39K sold.

Silvant Capital Management first reported a position in BIIB in Q1 2018 and held it in 16 quarters. The position peaked at $6.27M in Q3 2018. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

Silvant Capital Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
Silvant Capital Management sold 164 Biogen shares in Q1 2022, an estimated $39K.
Silvant Capital Management first reported a position in Biogen in Q1 2018 and held it in 16 quarters.
Silvant Capital Management's Biogen position peaked at $6.27M in Q3 2018.
951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Silvant Capital Management's 13F filing for Q1 2022, filed 5 May 2022.